

Cellular Differentiation Regulator BLIMP1 Induces Epstein-Barr Virus Latency in Epithelial and B Cells by Activating Transcription from the Latency Promoter

Journal of Virology

89, 1731-1743

DOI: [10.1128/jvi.02781-14](https://doi.org/10.1128/jvi.02781-14)

Citation Report

#	ARTICLE	IF	CITATIONS
1	5-hydroxymethylation of the EBV genome regulates the latent to lytic switch. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E7257-65.	3.3	28
2	The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Virologica Sinica, 2015, 30, 107-121.	1.2	86
3	Contribution of the Epstein-Barr Virus to the Pathogenesis of Hodgkin Lymphoma. Current Topics in Microbiology and Immunology, 2015, 390, 287-313.	0.7	17
4	The Epigenetic Life Cycle of Epstein-Barr Virus. Current Topics in Microbiology and Immunology, 2015, 390, 103-117.	0.7	39
5	Epstein-Barr Virus Lytic Cycle Reactivation. Current Topics in Microbiology and Immunology, 2015, 391, 237-261.	0.7	70
6	Agents and Approaches for Lytic Induction Therapy of Epstein-Barr Virus Associated Malignancies. , 2016, 6, .		2
7	Epstein-Barr Virus: Diseases Linked to Infection and Transformation. Frontiers in Microbiology, 2016, 7, 1602.	1.5	84
8	CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors. Cell Host and Microbe, 2017, 21, 580-591.e7.	5.1	113
9	Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling. Journal of Virology, 2017, 91, .	1.5	17
10	Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival. Molecular Immunology, 2017, 91, 8-16.	1.0	14
11	Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression. Cell Host and Microbe, 2017, 22, 61-73.e7.	5.1	102
12	Roles of Non-coding RNAs During Herpesvirus Infection. Current Topics in Microbiology and Immunology, 2017, 419, 243-280.	0.7	18
13	Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin. International Journal of Cancer, 2017, 140, 149-162.	2.3	48
14	Precision Molecular Pathology of Hodgkin Lymphoma. Molecular Pathology Library, 2018, , .	0.1	2
15	Epstein-Barr virus in the pathogenesis of oral cancers. Oral Diseases, 2018, 24, 497-508.	1.5	62
16	S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. Leukemia, 2018, 32, 214-223.	3.3	25
17	Role of EBV in Classical Hodgkin Lymphoma. Molecular Pathology Library, 2018, , 91-109.	0.1	1
18	Epstein-Barr Virus . , 2018, , .		0

#	ARTICLE	IF	CITATIONS
19	Epigenetic crossroads of the Epstein-Barr virus B-cell relationship. <i>Current Opinion in Virology</i> , 2018, 32, 15-23.	2.6	17
20	The Dynamic Roles of TGF- β Signalling in EBV-Associated Cancers. <i>Cancers</i> , 2018, 10, 247.	1.7	23
21	Epstein-Barr Virus Gene BART1 Expression is Regulated by the Epithelial Differentiation Factor β 1 in Undifferentiated Nasopharyngeal Carcinoma. <i>Cancers</i> , 2018, 10, 76.	1.7	14
22	CRISPR-Cas9 Genetic Analysis of Virus-Host Interactions. <i>Viruses</i> , 2018, 10, 55.	1.5	20
23	Interferon regulatory factor 8 regulates caspase-1 expression to facilitate Epstein-Barr virus reactivation in response to B cell receptor stimulation and chemical induction. <i>PLoS Pathogens</i> , 2018, 14, e1006868.	2.1	45
24	Pathogenesis of Human Gammaherpesviruses: Recent Advances. <i>Current Clinical Microbiology Reports</i> , 2019, 6, 166-174.	1.8	3
25	IL-10 knockdown with siRNA enhances the efficacy of Doxorubicin chemotherapy in EBV-positive tumors by inducing lytic cycle via PI3K/p38 MAPK/NF- κ B pathway. <i>Cancer Letters</i> , 2019, 462, 12-22.	3.2	23
26	Epstein-Barr Virus Infection Promotes Epithelial Cell Growth by Attenuating Differentiation-Dependent Exit from the Cell Cycle. <i>MBio</i> , 2019, 10, .	1.8	25
27	Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. <i>Nature Reviews Microbiology</i> , 2019, 17, 691-700.	13.6	254
28	Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr Virus: An analysis of a prospective study in southern China. <i>Cancer Medicine</i> , 2019, 8, 2561-2571.	1.3	19
29	Evolutionary effects of the AID/APOBEC family of mutagenic enzymes on human gamma-herpesviruses. <i>Virus Evolution</i> , 2019, 5, vey040.	2.2	27
30	Epstein-Barr virus microRNAs regulate B cell receptor signal transduction and lytic reactivation. <i>PLoS Pathogens</i> , 2019, 15, e1007535.	2.1	47
31	Inhibition of Epstein-Barr Virus Replication in Human Papillomavirus-Immortalized Keratinocytes. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
32	Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals. <i>Frontiers in Oncology</i> , 2020, 10, 1723.	1.3	34
33	Reactivation of Epstein-Barr Virus by HIF-1 α Requires p53. <i>Journal of Virology</i> , 2020, 94, .	1.5	12
34	MYC Controls the Epstein-Barr Virus Lytic Switch. <i>Molecular Cell</i> , 2020, 78, 653-669.e8.	4.5	67
35	Clinical Manifestations and Epigenetic Regulation of Oral Herpesvirus Infections. <i>Viruses</i> , 2021, 13, 681.	1.5	15
36	B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition. <i>MSphere</i> , 2021, 6, .	1.3	10

#	ARTICLE	IF	CITATIONS
37	Long non-coding RNAs in Epstein-Barr virus-related cancer. <i>Cancer Cell International</i> , 2021, 21, 278.	1.8	8
38	Roles of Lytic Viral Replication and Co-Infections in the Oncogenesis and Immune Control of the Epstein-Barr Virus. <i>Cancers</i> , 2021, 13, 2275.	1.7	4
39	Regulation of the Macroautophagic Machinery, Cellular Differentiation, and Immune Responses by Human Oncogenic β -Herpesviruses. <i>Viruses</i> , 2021, 13, 859.	1.5	0
40	The Role of Coinfections in the EBV-Host Broken Equilibrium. <i>Viruses</i> , 2021, 13, 1399.	1.5	7
41	MicroRNA and Other Non-Coding RNAs in Epstein-Barr Virus-Associated Cancers. <i>Cancers</i> , 2021, 13, 3909.	1.7	15
42	Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells. <i>PLoS Pathogens</i> , 2021, 17, e1009783.	2.1	9
43	Stress-Induced Epstein-Barr Virus Reactivation. <i>Biomolecules</i> , 2021, 11, 1380.	1.8	39
44	IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells. <i>Journal of General Virology</i> , 2019, 100, 851-862.	1.3	8
45	Herpesvirus latency. <i>Journal of Clinical Investigation</i> , 2020, 130, 3361-3369.	3.9	127
46	EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency. <i>PLoS Biology</i> , 2017, 15, e2001992.	2.6	50
47	Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells. <i>PLoS Pathogens</i> , 2015, 11, e1005195.	2.1	79
48	An Epstein-Barr Virus-Encoded Protein Complex Requires an Origin of Lytic Replication In Cis to Mediate Late Gene Transcription. <i>PLoS Pathogens</i> , 2016, 12, e1005718.	2.1	47
49	Hypoxia-inducible factor-1 α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter. <i>PLoS Pathogens</i> , 2017, 13, e1006404.	2.1	55
50	Murine gammaherpesvirus M2 antigen modulates splenic B cell activation and terminal differentiation in vivo. <i>PLoS Pathogens</i> , 2017, 13, e1006543.	2.1	10
51	Epigenetic Consequences of Epstein-Barr Virus Infection. <i>Epigenetics and Human Health</i> , 2017, , 65-87.	0.2	0
54	β -Np63 α promotes Epstein-Barr virus latency in undifferentiated epithelial cells. <i>PLoS Pathogens</i> , 2021, 17, e1010045.	2.1	8
55	Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation. <i>Viruses</i> , 2021, 13, 2344.	1.5	70
56	Epigenetic control of the Epstein-Barr lifecycle. <i>Current Opinion in Virology</i> , 2022, 52, 78-88.	2.6	21

#	ARTICLE	IF	CITATIONS
58	Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. <i>PLoS Pathogens</i> , 2022, 18, e1010453.	2.1	10
59	A Polymorphism in the Epstein-Barr Virus EBER2 Noncoding RNA Drives <i>In Vivo</i> Expansion of Latently Infected B Cells. <i>MBio</i> , 2022, 13, .	1.8	2
61	Natural killer cell responses to human oncogenic β -herpesvirus infections. <i>Seminars in Immunology</i> , 2022, 60, 101652.	2.7	5
62	Epstein-Barr Virus and Human Herpesvirus-6 Reactivation in Acute COVID-19 Patients. <i>Viruses</i> , 2022, 14, 1872.	1.5	19
63	Type 1 and Type 2 Epstein-Barr viruses induce proliferation, and inhibit differentiation, in infected telomerase-immortalized normal oral keratinocytes. <i>PLoS Pathogens</i> , 2022, 18, e1010868.	2.1	2
64	EBV Association with Lymphomas and Carcinomas in the Oral Compartment. <i>Viruses</i> , 2022, 14, 2700.	1.5	1
65	Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus. <i>Viruses</i> , 2022, 14, 2709.	1.5	7
66	A comprehensive single cell data analysis of lymphoblastoid cells reveals the role of super-enhancers in maintaining EBV latency. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
67	Retinoblastoma Protein Is Required for Epstein-Barr Virus Replication in Differentiated Epithelia. <i>Journal of Virology</i> , 2023, 97, .	1.5	2
68	Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome. <i>Journal of Virology</i> , 2023, 97, .	1.5	4
73	Perspicitve Chapter: Modulation of Latent to Lytic Cycle Infection Switch and its Implication in EBV Mediated Tumorigenicity. , 0, , .		0